The Virtues and Pitfalls of Implementing a New Test

Similar documents
2014 Continuing Compliance Master Series Best Practices in Alternative Assessment of Performance

Disclosures. Relevant Financial Relationship(s): Nothing to Disclose. Off Label Usage: Nothing to Disclose 9/19/2017. Proficiency Testing

Hemostasis Test Validation, Performance and Reference Intervals

METHOD VALIDATION: WHY, HOW AND WHEN?

Method Comparison Report Semi-Annual 1/5/2018

Basic knowledge of POCT instuments. The Tide Resort Bangsan Beach 18 June 2009

In Vitro Diagnostic Glucose Test System

Forum for Collaborative HIV Research External Validation of CD4 and Viral Load Assays Paris, France June 29, 2007

PROFICIENCY TESTING POLICY

It s Just a Waived Glucose, Isn t It?

METHOD VALIDATION CASE

GLUH PRINCIPLE REF B ANNUAL REVIEW Reviewed by. Date. Date INTENDED USE

Validation Case studies: the good, the bad and the molecular

Diagnostic reagent for quantitative in vitro determination of Urea / Blood Urea Nitrogen in serum, plasma and urine by colorimetry.

For In Vitro Diagnostic Use

Traditional approaches to Reference Intervals

It s a Gas! Issues in the Blood Gas Laboratory. D. Robert Dufour, MD, FCAP Consultant Pathologist VA Medical Center, Washington DC

Guide to Fulfillment of Measurement Uncertainty

Verification and validation of diagnostic laboratory tests in clinical virology

METHOD VALIDATION CASE

Compliance Issues in Off-Label Use of Blood Glucose Monitors

Performance Characteristics of a New Single-Sample Freezing Point Depression Osmometer

Individual Quality Control Plans (IQCP) Risk Assessment

INTERNAL QUALITY CONTROL ( Q I C) QC)

Polymer Technology Systems, Inc. CardioChek PA Comparison Study

Quality Control for Point-of-Care Testing

August 2017 Changes. Reproductive Laboratory Checklist. CAP Accreditation Program

The analytical phase

Case Studies, or Verification Vignettes

Manual. Transfer step. Figure 1. Workflow comparison of manual phenylalanine assay and automated GSP Neonatal Phenylalanine assay

USING THE ACCESS AMH ASSAY IN YOUR LABORATORY

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE

(a) y = 1.0x + 0.0; r = ; N = 60 (b) y = 1.0x + 0.0; r = ; N = Lot 1, Li-heparin whole blood, HbA1c (%)

A validation study of after reconstitution stability of diabetes: level 1 and diabetes level 2 controls

IDEXX Catalyst One Chemistry Analyzer for In-house Measurement of Total Thyroxine (TT 4 ) Concentration in Serum from Dogs and Cats

Selecting a Risk-Based SQC Procedure for a HbA1c Total QC Plan

Importance of Methodology Certification and Accreditations to Perform Assays. Stan Hamilton, MD Head, Pathology and Laboratory Medicine

POTASSIUM/K. 3.6 mmol/l

Delta Check Calculation Guide

Plasma Hemoglobin Determination: Two Manual Methods Compared. An Honors Thesis (HONRS 499) Anne M. Emerick. Sharlene Strahl. Beech Grove, Indiana

Proficiency Testing LABFACTS Requirements for good laboratory practice and COLA Laboratory Accreditation programs are underlined.

Standard Operating Procedure

FAQs for UK Pathology Departments

Quality Corner: Inspection Preparation By Rhonda Burgard, Client Services Supervisor

Performance Characteristics of Eight Estradiol Immunoassays

The use of QCMD proficiency testing panels in clinical virology.

Determination of hemoglobin is one of the most commonly

QMS TACROLIMUS APPLICATION BECKMAN COULTER AU480 /AU680 /AU5800

Topic: Q&A from CAP Webinar: Stay in Compliance With the CMS Directive Regarding PT Testing on Multiple Instruments Date: November 12, 2015

Using Blood Glucose Meters in the Hospital: Defining Critically Ill and Addressing Accreditation Issues

NJ RAPID HIV TESTING SUPPORT PROGRAM

G. Snodgrass, K. Ackles, A. Blanco and A. Versaggi Ortho Clinical Diagnostics, Rochester, NY 14626

Evaluation of the Precision and Accuracy of the INRatio 2 Prothrombin Time (PT) Monitoring System

Clinical Experience 2

Quality Specifications for POCT

Placement of Biomarker Analysis in a CLIA or Bioanalytical Laboratory

4/10/2017. Placement of Biomarker Analysis in a CLIA or Bioanalytical Laboratory

The Colorado Bureau of Investigation s (CBI) Blood Alcohol Analyses Summary of Issues

How Good is your INR? The Use of Certified Plasmas in PT/INR Testing. INR System. How Good is your INR? Outline

College of American Pathologists

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2017Oct27

C30-A2 ISBN ISSN Point-of-Care Blood Glucose Testing in Acute and Chronic Care Facilities; Approved Guideline Second Edition

LIPASE liquicolor. Design Verification. Multipurpose Reagent

Point of Care testing refers to all laboratory testing that is done outside of the walls of the clinical laboratory in the proximity of the patient.

Chapter 2. High-sensitivity C-reactive protein methods examined

CAP Accreditation of Genetics Testing Laboratories

INSTRUCTIONS FOR USE

C56-A Hemolysis, Icterus, and Lipemia/Turbidity Indices as Indicators of Interference in Clinical Laboratory Analysis; Approved Guideline

Evaluation Report: Eurolyser CRP test (ST0100 and ST0102) on. CUBE analyser (CA0100)

SQA-V Gold Semiannual Validation/Proficiency/QC Recommendations

SODIUM/NA. See below for information on factors affecting results. Certain substances, such as drugs, may affect analyte levels in vivo.

Evaluation of Cheongmeak DCS TM Reagents for Chemistry Analyzers

Digital Pathology and CAP Guidelines

PROFICIENCY TESTING. Clinical Laboratory Improvement Amendments (CLIA) DOs and DON Ts. Brochure # 8

This presentation focuses on recent changes in vaccine storage and handling requirements for the State Childhood Vaccine Program.

Direct HbA1c testing capabilities on the RX modena

Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer

liquicolor (AMP Buffer, IFCC) Design Verification

ACCESS hstni SCIENTIFIC LITERATURE

SCIEX Vitamin D 200M Assay for the Topaz System

Patient: 55 y female (ambulatory)

INSTRUCTIONS FOR USE

GUIDANCE DOCUMENTS CONTAINING THE COMMON PROVISIONS ON THE CONDUCT OF GCP INSPECTIONS BY COMPETENT AUTHORITIES OF THE DIFFERENT MEMBER STATES

Glucose Analytical Comparability Evaluation of the YSI 2300 STAT Plus and YSI 2900D Biochemistry Analyzers

Validation Report for the Neogen Fentanyl Kit for ELISA Screening of Whole Blood and Urine Specimens

STATE OPERATIONS MANUAL

Quality Control in the Chiropractic Clinical Setting Utilizing Thermography Instrumentation as a Model

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

NJ CBCT Regulation FAQ & Assistance

liquicolor Design Verification

2017 Drug Screening Code Updates for WV Medicaid. Prior Authorization for Drug Screening Codes Beyond Service Limits

DRUG TESTING POLICY. Policy Number: ADMINISTRATIVE T0 Effective Date: March 1, Related Policies None

Drug Testing Policy. Reimbursement Policy CMS Approved By. Policy Number. Annual Approval Date. Reimbursement Policy Oversight Committee

Pharmacogenomic Testing for Warfarin Response (NCD 90.1)

Rapid Detection FAQs

References Required document for Laboratory Accreditation by the College of American Pathologists.

Technical Bulletin No. 162

SAMPLE. Glucose Monitoring in Settings Without Laboratory Support

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2018Oct26

DRUG TESTING POLICY. Policy Number: ADMINISTRATIVE T0 Effective Date: January 1, Related Policies None

Transcription:

The Virtues and Pitfalls of Implementing a New Test James H. Nichols, Ph.D., DABCC, FACB Professor of Clinical Pathology, Microbiology and Immunology Associate Medical Director for Clinical Operations Medical Director, Clinical Chemistry Nashville, Tennessee, USA james.h.nichols@vanderbilt.edu 1 Objectives 1. Identify regulations governing laboratory quality 2. Recognize what needs to be done to validate a new test 3. Describe test performance characteristics 2 Case Study A neurology faculty member, Dr. Johnson, approaches you as laboratory director with a question. He is starting a research study for a new drug to treat epilepsy that is refractive to other treatments. Patients will be recruited from the neurology clinic in the hospital The study sponsor requests that all women of child bearing age have a negative urine pregnancy test before enrolling. The sponsor requires that study participants use a specific point of care pregnancy test to screen female patients. 3 1

Audience Poll Which of the following best describes your response to this request for a new POC pregnancy test? A. Allow Dr. Johnson to perform the test in the neurology clinic, since it is research and not for clinical purposes. B. Require Dr. Johnson to submit test performance data, operator training, evidence of QC, a draft procedure manual, and enrollment in proficiency testing for your Chair of Pathology to sign off C. Request that Dr. Johnson use the hospital s current POC kit or send the test to the core laboratory D. Nothing is required as urine pregnancy is CLIA waived, which means it is waived of all regulations 4 CLIA 88 Clinical Laboratory Improvement Amendments of 1988 Federal Regulatory Standards that apply to all clinical laboratory testing performed on humans in the United States Sets minimum guidelines for accuracy and reliability of laboratory testing Enforced through CMS Centers for Medicare and Medicaid Services Noncompliant labs can be sanctioned Lose ability to perform testing for up to 2 yrs Lab Directors cannot direct any other lab while sanctioned Cannot bill or be reimbursed by Medicare for 2 years Other state and accreditation agencies (Joint Commission and CAP) may have additional requirements 5 CLIA 88: Definitions CLIA does not apply to components or functions of: Research laboratories that test human specimens but do not report patient specific results for the diagnosis, prevention or treatment of any disease or impairment of, or the assessment of the health of individual patients. Determination of CLIA applicability depends on who has access to the result and how it may be utilized in the management of the patient CLIA also doesn t apply to forensic testing or labs certified by NIDA for drug testing performed to NIDA guidelines 6 2

Test Complexity Under CLIA 88 Tests are categorized as waived, moderate complexity, or high complexity depending on the following criteria: 1. Scientific and technical knowledge needed 2. Training and experience needed 3. Reagent and material preparation 4. Characteristics of operational steps 5. Calibration, quality control, and proficiency testing materials 6. Test system troubleshooting and equipment maintenance 7. Interpretation and judgment needed 7 CLIA Waived Complexity Testing Approved for home use So simple, no patient mismanagement even if performed incorrectly Lay person can get results comparable to laboratory technologist Labs have only 3 requirements! 1. Pay biennial fee (every 2 years) for CLIA certificate renewal 2. Follow manufacturers instructions for use 3. Allow the laboratory to be inspected Generally, for cause (patient complaint), Random state survey, Periodic inspections not required! Note: No method evaluation required! Moderate/High Complexity Tests Labs performing moderate or high complexity testing also have requirements for: Minimum education training and competency for lab director, supervisory and technical staff Test verification and periodic correlation of instrumentation Establishment of a quality control and assurance plan Enrollment in an external quality control (proficiency testing) program Maintenance, calibration and calibration verification Test ordering and reporting documentation 9 3

Validation vs Verification Validation establishing the performance specifications of a new diagnostic tool such as a new test, internally developed test or modified method Manufacturers or LDT s Verification A one time process to determine performance characteristics of a test before use in patient testing Verifying an already validated test! Joint Commission Regulations Joint Commission PA5.3.3 Validation of methods Before a new test is used to report individual results, it must be verified that the testing system will produce accurate results on a consistent and reliable basis. Joint Commission PA 5.3.3.1 As required, a system exists to evaluate/correlate the relationship between results for the same test performed with different methodologies or instruments or at different testing sites. CAP Regulations Method evaluation spread throughout checklist questions, examples: Equipment is approved by lab director. Acceptable limits set for daily QC Comparability of instrument/method for more than one method checked twice a year Criteria for calibration verification established AMR validation with matrix appropriate materials 4

Method Validation/Verification to CLIA Moderate Complexity Accuracy Precision Reportable Range Verify Reference Range High Complexity Accuracy Precision Analytical Sensitivity Analytical Specificity Reportable Range Reference Range(s) Establish calibration and control procedures Other performance criteria Laboratory Regulations General and open to some interpretation Direct what must be done, not how it is accomplished. How to meet the regulations: There is no one right way. Bottom line the institution will need to back their reasoning for what is done Consensus CLSI protocols Literature do what others have done Manufacturer s recommendations Balance cost and what is reasonable Precision Within run (Intra assay) Between run Day to day (Interassay or total) 5

CLSI EP 5 Familiarization (Days 1 4) Within run (Day 5) 20 tests 20 consecutive replicates/single run Total (Days 6 25) 80 tests 2 replicates/concentration level/run 2 runs/day x 20 days Calculate Mean, SD and CV CV = SD/Mean x 100 Audience Poll Which Best Describes the Precision Example? A. Good precision, acceptable B. Borderline acceptable, repeat study with another control C. Unknown, need more data D. Poor precision, unacceptable Manufacturer Specifications 6

Reportable Range (Linearity) Must establish reportable limits (undiluted) and maximum dilution Two pools (mixed) Spike low sample with known amount of analyte Dilute high sample with a blank Mix high and low sample to create a curve Standard reference materials CLSI EP 6 Familiarization (Days 1 5) Linearity (Day 6) 16 tests Dilute high sample with low (1:3, 1:1, 3:1) 4 reps at 4 levels/single run Evaluate linear fit XY plot Compare variance to ensure equivalence across levels Calculate slope, intercept, tolerance (Sy/x) Calculate lack of fit Forcing a Line on a Curve 7

Linearity and Spurious Points Linearity and Imprecision Audience Poll Which of the following is TRUE about the linearity figure? A. Linear, full range of data B. Linear, partial range of data C. Requires dilution study to make conclusion D. Non linear, unacceptable 8

Linearity Answer Audience Poll Which of the following is TRUE about the linearity figure? Albumin A. Linear, full range of data B. Linear, partial range of data C. Requires dilution study to make conclusion D. Non linear, unacceptable Reference Range Verify existing ranges Literature Manufacturer s Current method Construct new reference range Considerations Statistically relevant numbers Well vs sick patients Galen & Gambino Beyond Normality: The Predictive Value and Efficiency of Medical Diagnoses. 1975 John Wiley & Sons, New York Gräsbeck & Alström Reference Values in Laboratory Medicine 1981 John Wiley & Sons, New York 9

Albumin Reference Range Accuracy Bias to a reference method Absolute recovery to a known amount Relative match another method Reference method free of interferences Rarely happens in the real world CLSI EP 9 Familiarization (Days 1 5) Accuracy (Days 6 10) 160 tests Analyze >40 specimens in duplicate by both test and reference method over 5 days (8/day) Estimate bias Calculate regression statistics and plot slope (bias) intercept r (adequacy of range) standard error (Sy/x) confidence interval 10

Audience Poll Which of the following is TRUE about this HgbA1c Correlation? A. Good correlation, no issues B. Too much bias, question whether method will meet medical standards. C. Too much imprecision, could cause physician confusion if results mixed with core lab HgbA1c D. Poor correlation, generally bad correlation, consider repeating or picking new POC method Audience Poll Which of the following is TRUE about this Sodium Correlation? A. Good correlation, no issues B. Too much bias, question whether method will meet medical standards. C. Too much imprecision, could cause physician confusion if results mixed with core lab Sodium D. Poor correlation, generally bad correlation, consider repeating or picking new POC method Sodium Correlation 11

Other Considerations Method dependent Carry over CLSI EP 3 Analytical Sensitivity CLSI EP17 Absolute Limit of Detection Practical operating 2 3 x LOD (or > 2 10 SD) Interference CLSI EP 7 Paired Difference 2 pools (high 10x toxic) Dose Response linear increase to titrate interferent and determine tolerance K Hemolysis Interference K Icterus Interference 12

LDH Hemolysis Interference Summary Method evaluation is important to document initial performance, quality improvement and for future troubleshooting CLSI, the manufacturer and peer literature can all be resources for verification and validation protocols Precision, accuracy, reportable range and reference (normal) range must be evaluated, at a minimum, for all non waived tests before patient use No single how to manual for validation adapt standards as necessary for your lab Performance specifications are documented in Laboratory Procedure Manual for future reference In addition, new tests require a written procedure, documentation of training, QC, proficiency testing and ongoing periodic re evaluation necessary New reagent, control, calibrator lots/shipments Semi annually (calibration verification and correlation of instruments) 38 References Burtis, CA, Ashwood ER. (editors) Tietz Textbook of Clinical Chemistry, Third Edition. 1999, WB Saunders Co. Philadelphia PA. Clinical and Laboratory Standards Institute. Evaluation Protocols. Various publication dates. Wayne, PA. HCFA 42 CFR; Final Rule; Medicare, Medicaid and CLIA Programs; Regulations implementing Clinical Laboratories Improvement Amendments of 1988 (CLIA. Fed. Regist. 57;7001 288 (28 February 1992) Joint Commission on Accreditation of Healthcare Organizations CAMH Comprehensive Accreditation Manual for Hospitals. 2012 JCAHO, Oakbrook Terrace, IL. College of American Pathologists Commission on Laboratory Accreditation. Inspection Checklist. 2012 CAP, Northfield, IL. James GP, Bee DB. Evaluation of clinical laboratory instruments Part II: Use and abuse of statistical tools. Am J Med Technol 1981:47;303 10. 13